Browsing Tag
Tempus AI Inc.
3 posts
Moderna (MRNA) falls 18% despite melanoma win: Can an $81bn valuation hold?
Moderna shares plunged 17.57% despite positive Phase 3 melanoma data from its personalised mRNA cancer therapy developed with Merck. With an approximately $81 billion market valuation, continued operating losses and a commercial opportunity extending well beyond melanoma, the central question is how much future oncology success investors have already priced in.
Wall Street rally: Pegasystems, Summit Therapeutics among top gainers as trade optimism lifts US stocks
Find out how Pegasystems, Summit Therapeutics, and Tempus AI surged on April 23, 2025, as tariff cuts and AI optimism drove major gains across US stock markets.
Top US stocks crash as inflation shock and tariff war fuel Wall Street’s worst day in months
US stocks tumbled on April 8 as inflation data and escalating US-China tariffs triggered sharp losses in biotech, AI, lithium, and semiconductor stocks.